Related Experiment Videos
A comparability study of the emerging protein array platforms with established ELISA procedures.
Susan Pang1, Jodie Smith, David Onley
1LGC Ltd., Queens Road, Teddington, Middlesex, TW11 0LY, UK. Susan.Pang@lgc.co.uk
Journal of Immunological Methods
|July 5, 2005
Summary
Multiplexed microarray immunoassays offer high throughput but require careful validation. Establishing appropriate cut-off levels is crucial for accurate diagnostic results with these advanced array platforms.
Area of Science:
- Immunology and diagnostics
- Biotechnology and assay development
Background:
- Microarray technology enables multiplexed immunoassays for enhanced throughput analysis.
- Transitioning from uniplexed to multiplexed formats presents performance challenges.
Purpose of the Study:
- To assess performance characteristics of transferring immunoassays from uniplexed to multiplexed formats.
- To compare two solution phase array platforms: Luminex xMap and SmartBead UltraPlex.
Main Methods:
- Comparative study using a model system for detecting six autoantibodies in human serum samples.
- Evaluation of Luminex xMap and SmartBead UltraPlex technologies.
- Comparison of results with Enzyme-Linked Immunosorbent Assay (ELISA).
Main Results:
- Both Luminex xMap and SmartBead UltraPlex assays showed general comparability.
- Discrepancies were observed between array platforms and ELISA results.
- Variations in cut-off level assignment were identified as the primary cause of non-concordant results.
Conclusions:
- Array platforms demonstrate potential for immunodiagnostics.
- Accurate establishment of suitable cut-off levels is essential for reliable diagnostic applications.